US 11,986,478 B2
Targeting papain-like protease for broad-spectrum coronaviruses inhibition
Shuofeng Yuan, Hong Kong (CN); Fuk Woo Jasper Chan, Hong Kong (CN); and Kwok Yung Yuen, Hong Kong (CN)
Assigned to Versitech Limited, Hong Kong (CN); and Centre for Virology, Vaccinology and Therapeutics Limited, Hong Kong (CN)
Filed by Versitech Limited, Hong Kong (CN); and Centre for Virology, Vaccinology and Therapeutics Limited, Hong Kong (CN)
Filed on Aug. 31, 2022, as Appl. No. 17/823,559.
Claims priority of provisional application 63/260,771, filed on Aug. 31, 2021.
Prior Publication US 2023/0241067 A1, Aug. 3, 2023
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61P 31/14 (2006.01); C12Q 1/6888 (2018.01)
CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 31/14 (2018.01); C12Q 1/6888 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method for prophylactic or responsive treatment of a human coronavirus infection or a symptom thereof in a human subject, said method comprising administering an effective amount of a papain-like protease (PLpro) inhibitor to the human subject, wherein the PLpro inhibitor is F0213, according to formula (I); F0326, according to formula (II); and/or F0393, according to formula (III), or a pharmaceutically acceptable salt, derivative, or prodrug of any thereof:

OG Complex Work Unit Chemistry